Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Cathleen Concannon is active.

Publication


Featured researches published by Cathleen Concannon.


JAMA | 2015

Epidemiology of Carbapenem-Resistant Enterobacteriaceae in 7 US Communities, 2012-2013

Alice Guh; Sandra N. Bulens; Yi Mu; Jesse T. Jacob; Jessica Reno; Janine Scott; Lucy E. Wilson; Elisabeth Vaeth; Ruth Lynfield; Kristin M. Shaw; Paula Snippes Vagnone; Wendy Bamberg; Sarah J. Janelle; Ghinwa Dumyati; Cathleen Concannon; Zintars G. Beldavs; Margaret Cunningham; P. Maureen Cassidy; Erin C. Phipps; Nicole Kenslow; Tatiana Travis; David Lonsway; J. Kamile Rasheed; Brandi Limbago

IMPORTANCE Carbapenem-resistant Enterobacteriaceae (CRE) are increasingly reported worldwide as a cause of infections with high-mortality rates. Assessment of the US epidemiology of CRE is needed to inform national prevention efforts. OBJECTIVE To determine the population-based CRE incidence and describe the characteristics and resistance mechanism associated with isolates from 7 US geographical areas. DESIGN, SETTING, AND PARTICIPANTS Population- and laboratory-based active surveillance of CRE conducted among individuals living in 1 of 7 US metropolitan areas in Colorado, Georgia, Maryland, Minnesota, New Mexico, New York, and Oregon. Cases of CRE were defined as carbapenem-nonsusceptible (excluding ertapenem) and extended-spectrum cephalosporin-resistant Escherichia coli, Enterobacter aerogenes, Enterobacter cloacae complex, Klebsiella pneumoniae, or Klebsiella oxytoca that were recovered from sterile-site or urine cultures during 2012-2013. Case records were reviewed and molecular typing for common carbapenemases was performed. EXPOSURES Demographics, comorbidities, health care exposures, and culture source and location. MAIN OUTCOMES AND MEASURES Population-based CRE incidence, site-specific standardized incidence ratios (adjusted for age and race), and clinical and microbiological characteristics. RESULTS Among 599 CRE cases in 481 individuals, 520 (86.8%; 95% CI, 84.1%-89.5%) were isolated from urine and 68 (11.4%; 95% CI, 8.8%-13.9%) from blood. The median age was 66 years (95% CI, 62.1-65.4 years) and 284 (59.0%; 95% CI, 54.6%-63.5%) were female. The overall annual CRE incidence rate per 100<000 population was 2.93 (95% CI, 2.65-3.23). The CRE standardized incidence ratio was significantly higher than predicted for the sites in Georgia (1.65 [95% CI, 1.20-2.25]; P < .001), Maryland (1.44 [95% CI, 1.06-1.96]; P = .001), and New York (1.42 [95% CI, 1.05-1.92]; P = .048), and significantly lower than predicted for the sites in Colorado (0.53 [95% CI, 0.39-0.71]; P < .001), New Mexico (0.41 [95% CI, 0.30-0.55]; P = .01), and Oregon (0.28 [95% CI, 0.21-0.38]; P < .001). Most cases occurred in individuals with prior hospitalizations (399/531 [75.1%; 95% CI, 71.4%-78.8%]) or indwelling devices (382/525 [72.8%; 95% CI, 68.9%-76.6%]); 180 of 322 (55.9%; 95% CI, 50.0%-60.8%) admitted cases resulted in a discharge to a long-term care setting. Death occurred in 51 (9.0%; 95% CI, 6.6%-11.4%) cases, including in 25 of 91 cases (27.5%; 95% CI, 18.1%-36.8%) with CRE isolated from normally sterile sites. Of 188 isolates tested, 90 (47.9%; 95% CI, 40.6%-55.1%) produced a carbapenemase. CONCLUSIONS AND RELEVANCE In this population- and laboratory-based active surveillance system in 7 states, the incidence of CRE was 2.93 per 100<000 population. Most CRE cases were isolated from a urine source, and were associated with high prevalence of prior hospitalizations or indwelling devices, and discharge to long-term care settings.


Emerging Infectious Diseases | 2015

Improved Phenotype-Based Definition for Identifying Carbapenemase Producers among Carbapenem-Resistant Enterobacteriaceae

Nora Chea; Sandra N. Bulens; Thiphasone Kongphet-Tran; Ruth Lynfield; Kristin M. Shaw; Paula Snippes Vagnone; Marion Kainer; Daniel Muleta; Lucy E. Wilson; Elisabeth Vaeth; Ghinwa Dumyati; Cathleen Concannon; Erin C. Phipps; Karissa Culbreath; Sarah J. Janelle; Wendy Bamberg; Alice Guh; Brandi Limbago

A new, less restrictive definition increases detection of Klebsiella pneumoniae carbapenemase producers.


BMC Infectious Diseases | 2013

Validation of the chronic disease score-infectious disease (CDS-ID) for the prediction of hospital-associated clostridium difficile infection (CDI) within a retrospective cohort

Vanessa Stevens; Cathleen Concannon; Edwin van Wijngaarden; Jessina C. McGregor

BackgroundAggregate comorbidity scores are useful for summarizing risk and confounder control in studies of hospital-associated infections. The Chronic Disease Score – Infectious Diseases (CDS-ID) was developed for this purpose, but it has not been validated for use in studies of Clostridium difficile Infection (CDI). The aim of this study was to assess the discrimination, calibration and potential for confounder control of CDS-ID compared to age alone or individual comorbid conditions.MethodsSecondary analysis of a retrospective cohort study of adult inpatients with 2 or more days of antibiotic exposure at a tertiary care facility during 2005. Logistic regression models were used to predict the development of CDI up to 60 days post-discharge. Model discrimination and calibration were assessed using the c-statistic and Hosmer-Lemeshow (HL) tests, respectively. C-statistics were compared using chi-square tests.ResultsCDI developed in 185 out of 7,792 patients. The CDS-ID was a better standalone predictor of CDI than age (c-statistic 0.653 vs 0.609, P=0.04). The best discrimination was observed when CDS-ID and age were both used to predict CDI (c-statistic 0.680). All models had acceptable calibration (P>0.05).ConclusionThe CDS-ID is a valid tool for summarizing risk of CDI associated with comorbid conditions.


Open Forum Infectious Diseases | 2015

Risk Factors for Community-Associated Clostridium difficile Infection in Adults: A Case-Control Study

Alice Guh; Susan Hocevar Adkins; Qunna Li; Sandra N. Bulens; Monica M. Farley; Zirka Smith; Stacy M. Holzbauer; Tory Whitten; Erin C. Phipps; Emily B. Hancock; Ghinwa Dumyati; Cathleen Concannon; Marion Kainer; Brenda Rue; Carol Lyons; Danyel M Olson; Lucy E. Wilson; Rebecca Perlmutter; Lisa G. Winston; Erin Parker; Wendy Bamberg; Zintars G. Beldavs; Valerie Ocampo; Maria Karlsson; Dale N. Gerding; L. Clifford McDonald

Abstract Background An increasing proportion of Clostridium difficile infections (CDI) in the United States are community-associated (CA). We conducted a case-control study to identify CA-CDI risk factors. Methods We enrolled participants from 10 US sites during October 2014–March 2015. Case patients were defined as persons age ≥18 years with a positive C. difficile specimen collected as an outpatient or within 3 days of hospitalization who had no admission to a health care facility in the prior 12 weeks and no prior CDI diagnosis. Each case patient was matched to one control (persons without CDI). Participants were interviewed about relevant exposures; multivariate conditional logistic regression was performed. Results Of 226 pairs, 70.4% were female and 52.2% were ≥60 years old. More case patients than controls had prior outpatient health care (82.1% vs 57.9%; P < .0001) and antibiotic (62.2% vs 10.3%; P < .0001) exposures. In multivariate analysis, antibiotic exposure—that is, cephalosporin (adjusted matched odds ratio [AmOR], 19.02; 95% CI, 1.13–321.39), clindamycin (AmOR, 35.31; 95% CI, 4.01–311.14), fluoroquinolone (AmOR, 30.71; 95% CI, 2.77–340.05) and beta-lactam and/or beta-lactamase inhibitor combination (AmOR, 9.87; 95% CI, 2.76–340.05),—emergency department visit (AmOR, 17.37; 95% CI, 1.99–151.22), white race (AmOR 7.67; 95% CI, 2.34–25.20), cardiac disease (AmOR, 4.87; 95% CI, 1.20–19.80), chronic kidney disease (AmOR, 12.12; 95% CI, 1.24–118.89), and inflammatory bowel disease (AmOR, 5.13; 95% CI, 1.27–20.79) were associated with CA-CDI. Conclusions Antibiotics remain an important risk factor for CA-CDI, underscoring the importance of appropriate outpatient prescribing. Emergency departments might be an environmental source of CDI; further investigation of their contribution to CDI transmission is needed.


Infection Control and Hospital Epidemiology | 2014

The effect of multiple concurrent central venous catheters on central line-associated bloodstream infections.

Cathleen Concannon; Edwin van Wijngaarden; Vanessa Stevens; Ghinwa Dumyati

OBJECTIVE The current central line-associated bloodstream infection (CLABSI) surveillance rate calculation does not account for multiple concurrent central venous catheters (CVCs). The presence of multiple CVCs creates more points of entry into the bloodstream, potentially increasing CLABSI risk. Multiple CVCs may be used in sicker patients, making it difficult to separate the relative contributions of multiple CVCs and comorbidities to CLABSI risk. We explored the relative impact of multiple CVCs, patient comorbidities, and disease severity on the risk of CLABSI. DESIGN Case-control study. SETTING A total of 197 case patients and 201 control subjects with a CVC inserted during hospitalization at a tertiary care academic medical center from January 1, 2008, to December 31, 2010. METHODS Multiple CVCs was the exposure of interest; the primary outcome was CLABSI. Multivariable logistic regression was conducted to estimate odds ratios (ORs) and 95% confidence intervals (CIs) describing the association between CLABSI and multiple CVCs with and without controlling for Acute Physiology and Chronic Health Evaluation (APACHE) II and Charlson comorbidity index (CCI) scores as measures of disease severity and patient comorbidities, respectively. RESULTS Patients with multiple CVCs (n = 78) showed a 4.2 (95% CI, 2.2-8.4) times greater risk of CLABSI compared with patients with 1 CVC after adjusting for CLABSI risk factors. When including APACHE II and CCI scores, multiple CVCs remained an independent risk factor for CLABSI (OR, 3.4 [95% CI, 1.7-6.9]). CONCLUSIONS Multiple CVCs is an independent risk factor for CLABSI even after adjusting for severity of illness. Adjustment for this risk may be necessary to accurately compare rates between hospitals.


Journal of the American Medical Directors Association | 2016

Prevalence of Antimicrobial Use and Opportunities to Improve Prescribing Practices in U.S. Nursing Homes

Nicola D. Thompson; Lisa LaPlace; Lauren Epstein; Deborah L. Thompson; Ghinwa Dumyati; Cathleen Concannon; Gail Quinlan; Tory Witten; Linn Warnke; Ruth Lynfield; Meghan Maloney; Richard Melchreit; Nimalie D. Stone

OBJECTIVES To describe the prevalence and epidemiology of antimicrobial use (AU) in nursing home residents. DESIGN One-day point prevalence survey. SETTING AND PARTICIPANTS Nine nursing homes in four states; 1,272 eligible residents. MEASUREMENT Frequency of antimicrobials prescribed, drug name, start date, duration, route, rationale, and treatment site. AU prevalence per 100 residents overall and by resident characteristic. RESULTS AU prevalence was 11.1% (95% confidence interval, 9.4%-12.9%) and varied by resident characteristics. Most (32%) antimicrobials were given for urinary tract infection. For 38% of AU, key prescribing information was not documented. CONCLUSION Opportunities to improve AU documentation and prescribing exist in nursing homes.


Emerging Infectious Diseases | 2018

Carbapenem-Nonsusceptible Acinetobacter baumannii, 8 US Metropolitan Areas, 2012-2015.

Sandra N. Bulens; Sarah H. Yi; Maroya Spalding Walters; Jesse T. Jacob; Chris Bower; Jessica Reno; Lucy E. Wilson; Elisabeth Vaeth; Wendy Bamberg; Sarah J. Janelle; Ruth Lynfield; Paula Snippes Vagnone; Kristin M. Shaw; Marion Kainer; Daniel Muleta; Jacqueline Mounsey; Ghinwa Dumyati; Cathleen Concannon; Zintars G. Beldavs; P. Maureen Cassidy; Erin C. Phipps; Nicole Kenslow; Emily B. Hancock

In healthcare settings, Acinetobacter spp. bacteria commonly demonstrate antimicrobial resistance, making them a major treatment challenge. Nearly half of Acinetobacter organisms from clinical cultures in the United States are nonsusceptible to carbapenem antimicrobial drugs. During 2012–2015, we conducted laboratory- and population-based surveillance in selected metropolitan areas in Colorado, Georgia, Maryland, Minnesota, New Mexico, New York, Oregon, and Tennessee to determine the incidence of carbapenem-nonsusceptible A. baumannii cultured from urine or normally sterile sites and to describe the demographic and clinical characteristics of patients and cases. We identified 621 cases in 537 patients; crude annual incidence was 1.2 cases/100,000 persons. Among 598 cases for which complete data were available, 528 (88.3%) occurred among patients with exposure to a healthcare facility during the preceding year; 506 (84.6%) patients had an indwelling device. Although incidence was lower than for other healthcare-associated pathogens, cases were associated with substantial illness and death.


Infection Control and Hospital Epidemiology | 2017

Measuring Antibiotic Appropriateness for Urinary Tract Infections in Nursing Home Residents

Taniece Eure; Lisa LaPlace; Richard Melchreit; Meghan Maloney; Ruth Lynfield; Tory Whitten; Linn Warnke; Ghinwa Dumyati; Gail Quinlan; Cathleen Concannon; Deborah Thompson; Nimalie D. Stone; Nicola D. Thompson

We assessed the appropriateness of initiating antibiotics in 49 nursing home (NH) residents receiving antibiotics for urinary tract infection (UTI) using 3 published algorithms. Overall, 16 residents (32%) received prophylaxis, and among the 33 receiving treatment, the percentage of appropriate use ranged from 15% to 45%. Opportunities exist for improving UTI antibiotic prescribing in NH. Infect Control Hosp Epidemiol 2017;38:998-1001.


American Journal of Infection Control | 2014

Sustained reduction of central line-associated bloodstream infections outside the intensive care unit with a multimodal intervention focusing on central line maintenance.

Ghinwa Dumyati; Cathleen Concannon; Edwin van Wijngaarden; Tanzy Love; Paul S. Graman; Ann Marie Pettis; Linda Greene; Nayef El-Daher; Donna Farnsworth; Gail Quinlan; Gloria Karr; Lynnette Ward; Robin Knab; Mark Shelly


Open Forum Infectious Diseases | 2016

Surveillance for Carbapenem-Resistant Pseudomonas aeruginosa at Five United States Sites—2015

Maroya Spalding Walters; Sandra N. Bulens; Emily B. Hancock; Erin C. Phipps; Daniel Muleta; Jacquelyn Mounsey; Marion Kainer; Cathleen Concannon; Ghinwa Dumyati; Chris Bower; Jesse T. Jacob; P. Maureen Cassidy; Zintars G. Beldavs; Uzma Ansari; Valerie Albrecht; Maria Karlsson; J. Kamile Rasheed

Collaboration


Dive into the Cathleen Concannon's collaboration.

Top Co-Authors

Avatar

Ghinwa Dumyati

University of Rochester Medical Center

View shared research outputs
Top Co-Authors

Avatar

Ruth Lynfield

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Erin C. Phipps

University of New Mexico

View shared research outputs
Top Co-Authors

Avatar

Sandra N. Bulens

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Wendy Bamberg

Colorado Department of Public Health and Environment

View shared research outputs
Top Co-Authors

Avatar

Sarah J. Janelle

Colorado Department of Public Health and Environment

View shared research outputs
Top Co-Authors

Avatar

Lucy E. Wilson

Johns Hopkins University

View shared research outputs
Top Co-Authors

Avatar

Gail Quinlan

University of Rochester

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge